Scarica l'app Stockscreener
4.61
3.60%
0.16
Pre-mercato:
4.99
0.38
+8.24%
Trisalus Life Sciences Inc Borsa (TLSI) Ultime notizie
TriSalus initiates PREDICTT trial for liver tumor treatment By Investing.com - Investing.com South Africa
TriSalus initiates PREDICTT trial for liver tumor treatment - Investing.com
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors - Weekly Voice
Can pressure improve liver tumor treatment? TriSalus opens study at MD Anderson - Stock Titan
The stress test results at TriSalus (TLSIW) | TLSIW Latest Quarter Earnings: TriSalus has no EPS or revenue data this quarterIntrinsic Value - Newser
Tangible book value per share of TriSalus Life Sciences, Inc. – NASDAQ:TLSIW - TradingView
Tristar Acquisition I Corp (TRIS) - Minichart
TLSI Stock Price, Quote & Chart | TRISALUS LIFE SCIENCES INC (NASDAQ:TLSI) - ChartMill
TriSalus Life Sciences Announces Planned Clinical Leadership Transition - TipRanks
TriSalus Life Sciences (NASDAQ: TLSI) outlines key leadership transitions - Stock Titan
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
Quarterly results arrive before TriSalus' May 12 webcast - Stock Titan
JonesTrading Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Thought-leader group to discuss work-life balance - BizWest
TriSalus (TLSI) Stock: Buy Decision Analysis (Breakdown Watch) 2026-04-20Most Discussed Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Frankenius Equity swaps preferred for 759,000 TriSalus (TLSI) common shares - Stock Titan
TriSalus Life Sciences (NASDAQ:TLSI) Trading Up 2%Time to Buy? - MarketBeat
Bull Run: Will TriSalus Life Sciences Inc benefit from rate cuts2026 Retail & Weekly Hot Stock Watchlists - baoquankhu1.vn
Sentiment Recap: Is TriSalus Life Sciences Inc Equity Warrant a strong growth stock2026 Earnings Impact & Consistent Profit Alerts - baoquankhu1.vn
TLSI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Volume Summary: Is TriSalus Life Sciences Inc Equity Warrants growth already priced in2026 Price Swings & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Aug Swings: Is TriSalus Life Sciences Inc stock a value trap2026 Risk Factors & Reliable Price Breakout Signals - baoquankhu1.vn
TriSalus Life Sciences to Present New Data at 2026 Radiology Conference - National Today
TriSalus to present drug delivery data at radiology meeting By Investing.com - Investing.com South Africa
TriSalus to present drug delivery data at radiology meeting - Investing.com
TriSalus brings liver and uterine treatment data to SIR 2026 - Stock Titan
TriSalus to elevate director to chief medical officer role - BizWest
Trisalus Life Sciences, Inc. Appoints Richard Marshall, M.D., as Chief Medical Officer, Effective June 29, 2026 - marketscreener.com
TriSalus names Richard Marshall as chief medical officer By Investing.com - Investing.com India
TriSalus Life Sciences, Inc. Files Form 8-K on April 1, 2026 Announcing Press Release and Company Information - Minichart
TriSalus names Richard Marshall as chief medical officer - Investing.com
TriSalus Life Sciences Names Richard Marshall Chief Medical Officer - TipRanks
Transcend Appoints Elizabeth Jackson as Senior Vice President of Marketing - Weekly Voice
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer - Weekly Voice
Oncology company TriSalus taps interventional radiologist as medical chief - Stock Titan
TriSalus Life Sciences (TLSI) taps Richard Marshall, M.D., as Chief Medical Officer - Stock Titan
Will TriSalus (TLSI) Stock Rise in 2026 | Price at $4.11, Down 3.07%High Yield Stocks - Xã Thanh Hà
TLSI Technical Analysis & Stock Price Forecast - Intellectia AI
Laramie’s Unlocked Labs fights kidney stones with enzymes - BizWest
How does currency impact TriSalus (TLSI) Stock | Price at $4.24, Up 1.44%Social Buy Zones - Newser
Director converts 100,000 TriSalus (TLSI) preferred shares into common - Stock Titan
TLSI Should I Buy - Intellectia AI
Revenue Check: Why is TriSalus Life Sciences Inc stock going up2026 Key Highlights & Entry Point Confirmation Signals - baoquankhu1.vn
Aug PreEarnings: Is TriSalus Life Sciences Inc Equity Warrant in a long term uptrend2026 Market Mood & Technical Buy Zone Confirmation - baoquankhu1.vn
Executive pay and board elections at TriSalus (TLSI) 2026 virtual shareholder meeting - Stock Titan
Aug PreEarnings: Is TriSalus Life Sciences Inc Equity Warrants growth already priced inDip Buying & Weekly Top Performers Watchlists - baoquankhu1.vn
Published on: 2026-03-26 07:22:01 - baoquankhu1.vn
Momentum Shift: Does TriSalus Life Sciences Inc have pricing power2026 Top Gainers & Technical Confirmation Alerts - baoquankhu1.vn
What is Northland Securities' Estimate for TLSI Q1 Earnings? - MarketBeat
TLSI SEC FilingsTriSalus Life Sciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $17,998.54 in Stock - Defense World
Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $61,384.40 in Stock - Defense World
Weekly Earnings: Can TriSalus Life Sciences Inc Equity Warrant keep up with sector leadersMarket Risk Analysis & Fast Exit and Entry Trade Guides - baoquankhu1.vn
TriSalus Life Sciences launches proposed public stock offering - MSN
Aug Movers: Is TriSalus Life Sciences Inc Equity Warrant a top pick in the sector2026 Price Targets & Community Consensus Trade Signals - baoquankhu1.vn
RSI Check: Is TriSalus Life Sciences Inc Equity Warrant forming a bullish divergenceMarket Volume Summary & AI Powered Market Trend Analysis - baoquankhu1.vn
Top TriSalus Executives Make Major Moves With Insider Stock Sales - TipRanks
TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $17,998.54 in Stock - MarketBeat
TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $61,384.40 in Stock - MarketBeat
Szela, CEO of TriSalus, sells $79k in TLSI stock By Investing.com - Investing.com India
Szela, CEO of TriSalus, sells $79k in TLSI stock - Investing.com
TriSalus Life Sciences (TLSI) chief regulatory officer sells $14509 in stock - Investing.com
Trisalus Life Sciences’ CCO Marshak sells $14k in TLSI stock - Investing.com UK
0.41%
0.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):